Subsequently, Ixekizumab and Brodalumab were also authorized for the management of psoriasis and other conditions linked to IL-17 or IL-17R signaling (Lebwohl et al., 2015; Gordon et al., 2016; Armstrong and Read, 2020; Yiu et al., 2022). This evidence concerns the gene IL17RA and psoriasis.